Newer Molecules in the Treatment of Schizophrenia: A Clinical Update

Overview

Journal Indian J Pharmacol

Specialty Pharmacology

Date 2011 May 17

PMID 21572641

Citations 5

Authors

Abhishek Ghosh

Kaustav Chakraborty

Surendra Kumar Mattoo

Affiliations

Soon will be listed here.

Abstract

Schizophrenia is a heterogeneous psychiatric disorder in which multiple neurotransmitter systems have been implicated. Increased and decreased dopamine transmission in the subcortical meso-limbic and meso-cortical systems is closely linked to the "positive" and "negative" symptoms of schizophrenia, respectively. Important roles have also been found for serotonin and acetylcholine, both of which are closely linked to dopamine. An abnormality in glutamate functioning involving N-methyl-D-aspartic acid as well as other receptor subtypes may underlie the dopamine dysfunction observed in schizophrenia. Since the discovery of chlorpromazine in 1952, researchers have been developing new molecules targeting various neurotransmitter systems to maximize their efficacy and tolerability. The advancements in molecular genetics have opened up new horizons to manipulate the post-receptor protein cascade and gene expression. Although the magic-wand still eludes us, the newer molecules hold a lot of promise in this condition.

Citing Articles

Effect of Polymers and Permeation Enhancers in the Release of Quetiapine Fumarate Transdermal Patch through the Dialysis Membrane.

Bhupathyraaj M, Vijaya Rani K, Sridhar S, Shareef J, Thomas S, Halligudi N Polymers (Basel). 2022; 14(10).

PMID: 35631867 PMC: 9143260. DOI: 10.3390/polym14101984.

Zolpidem dependence in an adult with bipolar affective disorder and epilepsy: A case report.

Kar S, Dwivedi S Gen Psychiatr. 2019; 32(5):e100102.

PMID: 31552392 PMC: 6738692. DOI: 10.1136/gpsych-2019-100102.

Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine.

Anderson A, Gaffy C, Weseli J, Gorres K Viruses. 2019; 11(5).

PMID: 31108875 PMC: 6563273. DOI: 10.3390/v11050450.

Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride.

Deepak T, Raveesh B, Parashivamurthy B, Kumar M, Majgi S, Nagesh H J Clin Diagn Res. 2015; 9(6):FC07-10.

PMID: 26266134 PMC: 4525523. DOI: 10.7860/JCDR/2015/13007.6066.

Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics.

Crisafulli C, Chiesa A, Han C, Lee S, Park M, Balzarro B Eur Arch Psychiatry Clin Neurosci. 2011; 262(3):199-205.

PMID: 22120873 DOI: 10.1007/s00406-011-0278-3.

References

Leucht S, Davis J, Engel R, Kissling W, Kane J . Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. 2009; (438):7-14. DOI: 10.1111/j.1600-0447.2008.01308.x. View

Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker W . Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007; 61(8):1356-70. DOI: 10.1111/j.1742-1241.2007.01416.x. View

Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F . A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2008; 166(2):152-63. DOI: 10.1176/appi.ajp.2008.08030368. View

Peet M, Horrobin D . A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res. 2002; 36(1):7-18. DOI: 10.1016/s0022-3956(01)00048-6. View

Claustre Y, Peretti D, Brun P, Gueudet C, Allouard N, Alonso R . SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology. 2003; 28(12):2064-76. DOI: 10.1038/sj.npp.1300262. View

Martin L, Kem W, Freedman R . Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl). 2004; 174(1):54-64. DOI: 10.1007/s00213-003-1750-1. View

Javitt D, Duncan L, Balla A, Sershen H . Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry. 2004; 10(3):275-87. DOI: 10.1038/sj.mp.4001552. View

Tiihonen J, Hallikainen T, Ryynanen O, Repo-Tiihonen E, Kotilainen I, Eronen M . Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry. 2003; 54(11):1241-8. DOI: 10.1016/s0006-3223(03)00524-9. View

Kennett G, Wood M, Bright F, Trail B, Riley G, Holland V . SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997; 36(4-5):609-20. DOI: 10.1016/s0028-3908(97)00038-5. View

10.

Medhurst A, Atkins A, Beresford I, Brackenborough K, Briggs M, Calver A . GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther. 2007; 321(3):1032-45. DOI: 10.1124/jpet.107.120311. View

11.

Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt D . Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry. 2004; 56(6):441-6. DOI: 10.1016/j.biopsych.2004.06.029. View

12.

Marenco S, Egan M, Goldberg T, Knable M, McClure R, Winterer G . Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res. 2002; 57(2-3):221-6. DOI: 10.1016/s0920-9964(01)00311-5. View

13.

Wijtmans M, Leurs R, de Esch I . Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Investig Drugs. 2007; 16(7):967-85. DOI: 10.1517/13543784.16.7.967. View

14.

Dean B, Bymaster F, Scarr E . Muscarinic receptors in schizophrenia. Curr Mol Med. 2003; 3(5):419-26. DOI: 10.2174/1566524033479654. View

15.

Akbarian S . Restoring GABAergic signaling and neuronal synchrony in schizophrenia. Am J Psychiatry. 2008; 165(12):1507-9. DOI: 10.1176/appi.ajp.2008.08081225. View

16.

Buchanan R, Freedman R, Javitt D, Abi-Dargham A, Lieberman J . Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull. 2007; 33(5):1120-30. PMC: 2632365. DOI: 10.1093/schbul/sbm083. View

17.

Dunbar G, Boeijinga P, Demazieres A, Cisterni C, Kuchibhatla R, Wesnes K . Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl). 2007; 191(4):919-29. DOI: 10.1007/s00213-006-0675-x. View

18.

Marco N, Thirion A, Mons G, Bougault I, Le Fur G, Soubrie P . Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides. 1998; 32(5):481-8. DOI: 10.1016/s0143-4179(98)90075-0. View

19.

Goff D, Leahy L, Berman I, Posever T, Herz L, Leon A . A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol. 2001; 21(5):484-7. DOI: 10.1097/00004714-200110000-00005. View

20.

Roth B, Hanizavareh S, Blum A . Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl). 2004; 174(1):17-24. DOI: 10.1007/s00213-003-1683-8. View